# A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

> **NCT07011004** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse

## Interventions

- **BIOLOGICAL:** Cytokine Induced Memory-Like Natural Killer Cells
- **BIOLOGICAL:** Atezolizumb
- **BIOLOGICAL:** CIML-NK cell therapy

## Key facts

- **NCT ID:** NCT07011004
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011004, "A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07011004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*